Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results & 2021 Financial Guidance at 8 a.m. ET on Febru...
2021年1月9日 - 5:01AM
ビジネスワイヤ(英語)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today that it will issue a press release on its fourth
quarter and full year 2020 financial results, as well as on its
financial guidance for 2021, on Wednesday, February 10, 2021 at
7:00 a.m. ET. Following the release, Teva will conduct a conference
call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at
least 10 minutes before the scheduled start time): United States
1-866-966-1396; Israel 1-809-203-624 or International +44 (0) 2071
928000; passcode: 5458315.
A live webcast of the call will be available on Teva's website
at: http://ir.tevapharm.com/. Please log in at least 10 minutes
prior to the conference call in order to download the applicable
audio software.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on the Company's website or by
calling United States 1-866-331-1332; International +44 (0) 3333
009785; passcode: 5458315.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2019 and our Quarterly Reports
on Form 10-Q for the first and second quarters of 2020, including
in the sections captioned “Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210108005536/en/
IR Contacts United States Kevin C. Mannix (215)
591-8912
Israel Yael Ashman +972 (3) 914 8262
PR Contacts United States Kelley Dougherty (973)
832-2810
Israel Yonatan Beker +972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024